Protocol Ledger

NCT04126733 · Phase II · COMPLETED

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsate

Interventional Phase II clinical trial protocol NCT04126733 sponsored by Bayer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-14 Enrollment: 70 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04126733
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04126733
Protocol FieldVerified Registry Value
NCT IdentifierNCT04126733
Consolidated Lead SponsorBayer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment70 participants (ACTUAL)
Registered Start Date2019-10-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04126733
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
Sarah Cannon Research Institute (Nashville)Nashville, TNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI